Clara Montagut
About
Clara Montagut is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Clara Montagut has authored 81 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 37 papers in Cancer Research and 32 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Clara Montagut's work include Colorectal Cancer Treatments and Studies (35 papers), Cancer Genomics and Diagnostics (30 papers) and Lung Cancer Treatments and Mutations (21 papers). Clara Montagut is often cited by papers focused on Colorectal Cancer Treatments and Studies (35 papers), Cancer Genomics and Diagnostics (30 papers) and Lung Cancer Treatments and Mutations (21 papers). Clara Montagut collaborates with scholars based in Spain, United States and Italy. Clara Montagut's co-authors include Jeff Settleman, Joan Albanell, Ana Rovira, Beatríz Bellosillo, Joana Vidal, Ultan McDermott, Lindsey E. Ulkus, Anurag Singh, Toshi Shioda and Sreenath V. Sharma and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Molecular Cell.
In The Last Decade
Clara Montagut
76 papers receiving 2.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Clara Montagut Spain | 24 | 1.7k | 1.3k | 1.1k | 740 | 723 | 81 | 2.9k | ||
| Simona Lamba Italy | 25 | 1.5k 0.9× | 1.5k 1.1× | 1.0k 0.9× | 760 1.0× | 713 1.0× | 39 | 3.3k | ||
| Hiromichi Ebi Japan | 29 | 2.0k 1.2× | 2.5k 1.9× | 1.0k 0.9× | 1.3k 1.8× | 662 0.9× | 87 | 4.0k | ||
| Hitoshi Zembutsu Japan | 33 | 1.5k 0.9× | 1.5k 1.1× | 834 0.7× | 549 0.7× | 355 0.5× | 76 | 3.8k | ||
| Paul Roepman Netherlands | 26 | 1.4k 0.8× | 1.3k 1.0× | 1.1k 1.0× | 600 0.8× | 673 0.9× | 82 | 2.9k | ||
| Sandra O’Toole Australia | 35 | 1.9k 1.1× | 2.5k 1.9× | 1.4k 1.2× | 1.0k 1.4× | 356 0.5× | 105 | 4.3k | ||
| Anthony M. D’Amelio United States | 16 | 1.4k 0.8× | 1.4k 1.1× | 697 0.6× | 1.6k 2.1× | 459 0.6× | 37 | 2.9k | ||
| Ludmila Prudkin United States | 23 | 1.9k 1.1× | 1.7k 1.3× | 1.5k 1.4× | 804 1.1× | 537 0.7× | 50 | 3.8k | ||
| Paola Ulivi Italy | 34 | 1.7k 1.0× | 1.5k 1.1× | 1.4k 1.2× | 1.3k 1.7× | 484 0.7× | 182 | 3.7k | ||
| Sidong Huang Canada | 22 | 1.2k 0.7× | 1.9k 1.4× | 621 0.6× | 404 0.5× | 518 0.7× | 44 | 2.9k | ||
| Gaia Schiavon United Kingdom | 28 | 2.5k 1.5× | 1.5k 1.1× | 1.9k 1.7× | 1.7k 2.3× | 644 0.9× | 105 | 4.6k |
Countries citing papers authored by Clara Montagut
Since
Specialization
Citations
This map shows the geographic impact of Clara Montagut's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clara Montagut with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clara Montagut more than expected).
Fields of papers citing papers by Clara Montagut
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Clara Montagut. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clara Montagut. The network helps show where Clara Montagut may publish in the future.
Co-authorship network of co-authors of Clara Montagut
This figure shows the co-authorship network connecting the top 25 collaborators of Clara Montagut. A scholar is included among the top collaborators of Clara Montagut based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clara Montagut. Clara Montagut is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Martelli, Valentino, Joana Vidal, Sílvia Salvans, et al.. (2025). Liquid Biopsy in Peritoneal Carcinomatosis from Colorectal Cancer: Current Evidence and Future Perspectives. Cancers. 17(9). 1461–1461.
2.
Montagut, Clara, Joana Vidal, Vicente Alonso-Orduña, et al.. (2025). LBA33 Circulating tumor (ct) DNA-guided anti-EGFR rechallenge strategy in metastatic colorectal cancer (mCRC): Final results of the phase II randomized CITRIC trial. Annals of Oncology. 36. S1576–S1577.
3.
Ríos-Hoyo, Alejandro, et al.. (2024). Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road. Frontiers in Pharmacology. 15. 1398419–1398419.
4.
Foote, Michael B., James R. White, Walid K. Chatila, et al.. (2024). Analysis of Shared Variants between Cancer Biospecimens. Clinical Cancer Research. 31(2). 376–386.
5.
Cremolini, Chiara, Clara Montagut, Philippe Ronga, et al.. (2023). Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. Frontiers in Oncology. 12. 946850–946850.
6.
Bessa, Xavier, Joana Vidal, Catalina Márquez-Vega, et al.. (2023). High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer. Annals of Oncology. 34(12). 1187–1193.
7.
Vidal, Joana, David Casadevall, Beatríz Bellosillo, et al.. (2021). Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial. Clinical Cancer Research. 27(10). 2890–2898.
8.
Benavides, Manuel, Auxiliadora Gómez‐España, Pilar García‐Alfonso, et al.. (2021). Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). European Journal of Surgical Oncology. 48(5). 1123–1132.
9.
Schoemaker, Rik C., Clara Montagut, Scott Kopetz, et al.. (2019). Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors. Journal of Pharmacokinetics and Pharmacodynamics. 47(1). 5–18.
10.
Taı̈eb, Julien, Andreas Jung, Andrea Sartore‐Bianchi, et al.. (2019). The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. Drugs. 79(13). 1375–1394.
11.
Sánchez-Martín, Francisco Javier, Oriol Arpí, Laura Visa, et al.. (2019). HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer. Molecular Cancer Therapeutics. 18(11). 2135–2145.
12.
Fernández-Martos, Carlos, Carles Pericay, Ferrán Losa, et al.. (2019). Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma. JAMA Oncology. 5(11). 1566–1566.
13.
García‐Alfonso, Pilar, Manuel Benavides, E. Falcó, et al.. (2018). Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). The Oncologist. 23(11). 1271–e128.
14.
Goldberg, Richard M., Clara Montagut, Zev A. Wainberg, et al.. (2018). Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. ESMO Open. 3(4). e000353–e000353.
15.
Cutsem, Eric Van, Pieter‐Jan Cuyle, Sanne C.F.A. Huijberts, et al.. (2018). BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.. Journal of Clinical Oncology. 36(4_suppl). 627–627.
16.
Azuara, Daniel, Cristina Santos, Adriana López‐Doriga, et al.. (2016). Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies. Molecular Cancer Therapeutics. 15(5). 1106–1112.
17.
Melchior, Linea Cecilie, Morten Grauslund, Beatríz Bellosillo, et al.. (2015). Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma. Experimental and Molecular Pathology. 99(3). 485–491.
18.
Vidal, Joana, et al.. (2015). Hypersensitivity reaction caused by folinic acid administration: a case report and literature review. Journal of Chemotherapy. 28(6). 500–505.
19.
Pera, Miguél, R. Gallego, Clara Montagut, et al.. (2011). Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Annals of Oncology. 23(3). 664–670.
20.
Montagut, Clara, Sreenath V. Sharma, Toshi Shioda, et al.. (2008). Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma. Cancer Research. 68(12). 4853–4861.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Simona Lamba Breakdown of academic impact, for papers by Hiromichi Ebi Breakdown of academic impact, for papers by Hitoshi Zembutsu Breakdown of academic impact, for papers by Paul Roepman Breakdown of academic impact, for papers by Sandra O’Toole Breakdown of academic impact, for papers by Anthony M. D’Amelio Breakdown of academic impact, for papers by Ludmila Prudkin Breakdown of academic impact, for papers by Paola Ulivi Breakdown of academic impact, for papers by Sidong Huang Breakdown of academic impact, for papers by Gaia Schiavon